US2017210789A1PendingUtilityA1

Serum albumin binding proteins

Assignee: ABLYNX NVPriority: Jun 23, 2011Filed: Jan 3, 2017Published: Jul 27, 2017
Est. expiryJun 23, 2031(~4.9 yrs left)· nominal 20-yr term from priority
C07K 16/18C07K 2317/567C07K 2317/94C07K 16/32C07K 2317/565C07K 2317/569C07K 2317/31C07K 2317/92C07K 2317/22C07K 2317/24C07K 16/2863C07K 2317/76C07K 2317/14C07K 2319/01A61P 35/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.

Claims

exact text as granted — not AI-modified
1 . Polypeptide, protein, construct, compound or other chemical entity that comprises or essentially consists of the amino acid sequence Alb-23 (SEQ ID NO:1) or a variant of Alb-23 which is capable of specifically binding to human serum albumin and in which the amino acid residue at position 5 is L, the amino acid residue at position 16 is G, the amino acid residues at positions 44 and 45 are GP, the amino acid residues at positions 74 to 76 are SKN, and the amino acid residue at position 83 is R, and one or more (such as one or two) other immunoglobulin single variable domains. 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . Polypeptide, protein, construct, compound or other chemical entity according to  claim 1 , in which said one or more (such as one or two) other immunoglobulin single variable domains are one or more (such as one or two) therapeutic immunoglobulin single variable domains. 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . Polypeptide, protein construct, compound or other chemical entity according to  claim 1 , in which said one or more (such as one or two other immunoglobulin single variable domains are immunoglobulin single variable domains that comprise at least two disulphide bridges. 
     
     
         8 . Polypeptide, protein construct, compound or other chemical entity according to  claim 1 , in which at least one (and up to all) of the other immunoglobulin single variable domains is a Nanobody of VHH Class I. 
     
     
         9 .- 13 . (canceled)

Join the waitlist — get patent alerts

Track US2017210789A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.